This pioneering approach represents the initial use of cationic liposomes to concurrently safeguard mRNA integrity and increase the immunogenicity of tumor cells through the upregulation of MHC-I expression and the reduction in PD-L1 levels. This evidence concerns the gene CD274 and neoplasm.